Table 1 Select phase III clinical trials of ICI used in combination in RCC
Clinical trial | Patients | Arms | Primary completion date |
---|---|---|---|
CheckMate 214 (NCT02231749) | 1096 | Nivolumab + ipilimumab (n = 550) vs sunitinib (n = 546) | June 26, 2017 (reported) |
IMmotion151 (NCT02420821) | 915 | Atezolizumab + bevacizumab (n = 454) vs sunitinib (n = 461) | December 2017 (reported) |
JAVELIN Renal 101 (NCT02684006) | 830 (estimated) | Avelumab + axitinib vs sunitinib | December 2, 2018 (estimated) |
E7080-G000-307 (NCTNCT02811861) | 734 (estimated) | Lenvatinib + pembrolizumab vs Lenvatinib + everolimus vs sunitinib | January 15, 2020 (estimated) |
KEYNOTE-426 (NCT02853331) | 840 (estimated) | Pembrolizumab + axitinib vs sunitinib | January 27, 2020 (estimated) |
CheckMate 9ER (NCT03141177) | 1014 (estimated) | Nivolumab + cabozantinib vs sunitinib | February 15, 2021 (estimated) |